Medications for Addiction Treatment (MAT) for Substance Use Disorders involves a combination of medications that targets the brain, and psychosocial interventions (e.g., counseling, skills development) aimed at improving treatment outcomes. Research shows that medications and therapy together may be more successful than either treatment method alone.
This interactive MAT Waiver Eligibility Training provides comprehensive, evidence-based information that aims to help healthcare professionals determine the most clinically appropriate approach and informs individualized treatment decisions. This training will be particularly useful for providers of Opioid Use Disorder (OUD) treatment in pregnant and post-partum women.
This training is targeted towards physicians, nurses, physician assistants, social workers, LPCs, and addictions professionals who treat opioid use disorder (OUD). The training will be especially useful for those who treat pregnant and post-partum women.
For more information, please contact Ginger Polozoff at tip0001@hsc.wvu.edu
Presenter:
Patrick Marshalek, MD
Vice Chair Inpatient Clinical Operations, Associate Professor, Department of Behavioral Medicine & Psychiatry, WVU School of Medicine
Patrick Marshalek, MD is an Associate Professor and the Vice Chair of Inpatient Clinical Operations within the Department of Behavioral Medicine and Psychiatry at West Virginia University (WVU) School of Medicine. As a psychiatrist with an addiction medicine certification, his primary areas of clinical work are inpatient consultative and emergency services, medication-assisted treatment (MAT), and neuromodulation. Specifically, he is the Director of the Substance Use Disorder Consultation Service at WVU Medicine’s Ruby Memorial Hospital, where he provides consultative care for patients with opioid use disorder and mental illness. In regard to MAT, he has collaborated on the development of an innovative multidisciplinary program within the department to treat opioid dependent patients entitled, “Comprehensive Opioid Addiction Treatment” (COAT). Additionally, he has collaborated on the development of sub-specialized programming based on the aforementioned model for pregnant and postpartum women, as well as those suffering from chronic pain comorbidity. In regard to neuromodulation, he has provided ECT, TMS, and ketamine clinically to patients with treatment refractory depression, and has worked more recently on the development of an ambulatory service line directed towards those suffering from treatment resistant depression.
Presenter:
Zachary Hansen, MD
Medical Director of the Division of Addiction Sciences, Marshall Health - Department of Family Medicine Huntington, WV
Zachary Hansen, MD is the Medical Director of the Division of Addiction Sciences for Marshall Health. He received his medical degree from the Joan C. Edwards School of Medicine at Marshall University in 2004 and completed his residency in Family Medicine in 2006 via the Marshall University School of Medicine Family Medicine department. He has maintained his Board Certification in Family Medicine since 2006. From 2006 to 2020, he has worked for Valley Health Systems, based out of Huntington, WV and dedicated his time to providing quality healthcare to all individuals, emphasizing those who are underserved. In 2010, he obtained the DATA 2000 waiver and started to build his addiction medicine practice. He was instrumental in creating ProAct, provider response organization for addiction care and treatment, a collaboration between the two local hospitals, Cabell Huntington and St. Mary’s, as well as Valley Health, Marshall Health, and Thomas Health. These partners bring together behavioral, social, and medical resources from the community to provide comprehensive care for those seeking treatment for substance use disorders.
Following this course, you should be able to...
- Define opioid use disorder and describe its presentation among pregnant and post-partum women.
- Screen for opioid use disorder in pregnant and post-partum women.
- Provide evidence-based treatment for opioid use disorder in pregnant and post-partum women, including provision of buprenorphine.
- Support families of adolescents and young adults with opioid use disorder in treatment and recovery.
The overarching goal of PCSS is to train a diverse range of healthcare professionals in the safe and effective prescribing of opioid medications for the treatment of pain, as well as the treatment of substance use disorders, particularly opioid use disorders, with Medications for Addiction Treatment (MAT).
This is the first four hours of the 8-hour waiver training. Participants must complete four more hours of online self-study that will be sent to participants after the training. Nurse Practitioners and PAs must complete an additional 16 hours of training before applying for the waiver.
AAAP is the Data Sponsor for this waiver training.
Continuing education credits are pending for multiple disciplines.
ACCME Statement and Disclosure Statement
mail: pcss@aaap.org | Website: pcssNOW.org
CME Statement:
- This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the WVU School of Medicine and SAMHSA and the AAAP PCSS. The WVU School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- The WVU Office of CME designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Statement:
- This continuing education activity has been provided by the WVU School of Nursing for 4.7 contact hours. Of the total hours earned, 3.2 will be in the area of pharmacology consistent with the advanced pharmacology / pharmacotherapeutic competencies of advanced practice nursing. The WVU School of Nursing is an approved provider of continuing education by the State of West Virginia Board of Examiners for Registered Professional Nurses, Legislative Rule #19CSR11-4 under provider number 50-26086.
Disclosure: All those in a position to control content have indicated they have no relevant financial relationships to disclose.
Funding language:
This training is supported by the Centers for Medicare & Medicaid Services (CMS) of the U.S. Department of Health Services (HHS) as part of a financial assistance award totaling $2,204,124 with 98 percent funding from CMS/HHS and no funding by nongovernment source(s). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CMS/HHS, or the U.S. Government.
Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.